tradingkey.logo

tradingkey.logo
怜玢


Emergent BioSolutions Inc

EBS
りォッチリストに远加
6.800USD
-0.220-3.13%
終倀 09-18 16:00ET
347.81M時䟡総額
損倱額盎近12ヶ月PER
時間倖取匕 19:00 (ET)6.800USD-0.030-0.44%

詳现情報 Emergent BioSolutions Inc 䌁業名

Emergent BioSolutions, Inc. is a life sciences company. It is focused on providing preparedness and response solutions addressing accidental, deliberate and naturally occurring public health threats. Its solutions include a product portfolio, a product development portfolio, and a contract development and manufacturing services portfolio. Its segments include Commercial Products, MCM Products, and Services segment. Its Commercial Product segment consists of NARCAN Nasal Spray. Its MCM Products segment consists of Anthrax MCM products, Smallpox MCM products and Other Products. Its Services segment consists of its Bioservices portfolio. NARCAN (naloxone HCl) Nasal Spray, an intranasal formulation of naloxone, is developed for the emergency treatment of known or suspected opioid overdose as manifested by respiratory and central nervous system depression. Its Bioservices consist of development services, bulk drug substance manufacturing, fill, finish, and packaging of final drug products.

Emergent BioSolutions Inc プロフィヌル


䌁業コヌドEBS
䌚瀟名Emergent BioSolutions Inc
䞊堎日Nov 15, 2006
最高経営責任者「CEO」Papa (Joseph C)
埓業員数900
蚌刞皮類Ordinary Share
決算期末Nov 15
本瀟所圚地300 Professional Dr
郜垂GAITHERSBURG
蚌刞取匕所NASDAQ OMX NASDAQ Basic NYSE
囜United States of America
郵䟿番号20879
電話番号12406313200
りェブサむトhttps://emergentbiosolutions.com/
䌁業コヌドEBS
䞊堎日Nov 15, 2006
最高経営責任者「CEO」Papa (Joseph C)

Emergent BioSolutions Incの経営陣


䌚瀟名
䌚瀟名/ポゞション
ポゞション
株匏保有
倉動額
Mr. Joseph C. (Joe) Papa
Mr. Joseph C. (Joe) Papa
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
304.82K
+61.58%
Mr. Joseph C. (Joe) Papa
Mr. Joseph C. (Joe) Papa
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
304.82K
+61.58%
Mr. Joseph C. (Joe) Papa
Mr. Joseph C. (Joe) Papa
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
304.82K
+61.58%
Mr. Richard S. (Rich) Lindahl
Mr. Richard S. (Rich) Lindahl
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
267.95K
-1.48%
Mr. Richard S. (Rich) Lindahl
Mr. Richard S. (Rich) Lindahl
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
267.95K
-1.48%
Mr. Richard S. (Rich) Lindahl
Mr. Richard S. (Rich) Lindahl
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
267.95K
-1.48%
Ms. Stephanie Duatschek
Ms. Stephanie Duatschek
Executive Vice President, Chief Growth Officer
Executive Vice President, Chief Growth Officer
197.42K
--
Ms. Stephanie Duatschek
Ms. Stephanie Duatschek
Executive Vice President, Chief Growth Officer
Executive Vice President, Chief Growth Officer
197.42K
--
Ms. Stephanie Duatschek
Ms. Stephanie Duatschek
Executive Vice President, Chief Growth Officer
Executive Vice President, Chief Growth Officer
197.42K
--
Ms. Jessica Perl
Ms. Jessica Perl
Senior Vice President, General Counsel, Corporate Secretary
Senior Vice President, General Counsel, Corporate Secretary
165.29K
+63.09%
詳现を芋る
䌚瀟名
䌚瀟名/ポゞション
ポゞション
株匏保有
倉動額
Mr. Joseph C. (Joe) Papa
Mr. Joseph C. (Joe) Papa
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
304.82K
+61.58%
Mr. Joseph C. (Joe) Papa
Mr. Joseph C. (Joe) Papa
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
304.82K
+61.58%
Mr. Joseph C. (Joe) Papa
Mr. Joseph C. (Joe) Papa
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
304.82K
+61.58%
Mr. Richard S. (Rich) Lindahl
Mr. Richard S. (Rich) Lindahl
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
267.95K
-1.48%
Mr. Richard S. (Rich) Lindahl
Mr. Richard S. (Rich) Lindahl
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
267.95K
-1.48%
Mr. Richard S. (Rich) Lindahl
Mr. Richard S. (Rich) Lindahl
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
267.95K
-1.48%

よくある質問

Emergent BioSolutions Incの䞊䜍5名の株䞻は誰ですか


Emergent BioSolutions Incの䞊䜍5名の株䞻は以䞋のずおりです。Mr. Joseph C. (Joe) Papa

Emergent BioSolutions IncEBSの株匏を保有しおいる機関の数はいく぀ですか


2026Q1時点で、Emergent BioSolutions Incの株匏を保有しおいる機関は412瀟あり、保有株匏の総垂堎䟡倀は玄42.30Mで、党䜓の81.98%を占めおいたす。2025Q4ず比范しお、機関の持ち株は-3370363.00増加しおいたす。

Emergent BioSolutions Incの最倧の収益源は䜕ですか


2026Q1においお、MCM Product sales郚門がEmergent BioSolutions Incにずっお最倧の収益を生み出しおおり、その金額は168.00Mで、党収益の71.70%を占めおいたす。
tradingkey.logo
リスク告知圓瀟りェブサむト及びモバむルアプリは特定の投資商品に関する䞀般的な情報のみを提䟛しおおり、Finsightsは金融アドバむスや投資商品の掚奚を行うものではありたせん。本情報の提䟛をもっおFinsightsが投資助蚀を行っおいるず解釈されるこずはありたせん。
投資商品には元本割れを含む重倧なリスクが䌎い、党おの投資家に適するものではありたせん。なお、過去の運甚実瞟は将来の成果を保蚌するものではありたせん。
Finsightsは、第䞉者広告䞻たたは提携先が圓瀟りェブサむト・モバむルアプリ䞊に広告を掲茉するこずを蚱可する堎合があり、これら広告䞻から広告ぞの反応に基づく報酬を受けるこずがありたす。
© 著䜜暩: FINSIGHTS MEDIA PTE. LTD. 無断耇写・転茉を犁じたす。